Weatherford International Beats Estimates; Cytokinetics Announces Disappointing Tirasemtiv Results

Follow this company

Companies Mentioned

NYSE:wft / NASDAQ:yndx / PK:vape / NASDAQ:cytk
04/28/2014 [ACCESSWIRE]

Weatherford International Ltd. (NYSE: WFT) – For an in-depth report on Weatherford International Ltd. follow:

Shares of WFT closed up nearly 12% this past Friday, and was one of the biggest advancers on the NYSE. The stock hit a new 52-week high of $20.58 during intra-day trading and traded nearly 36.7 million shares. The company reported earnings with revenue for the first quarter being down 6.3% from a year ago, to $3.6 billion. This came in below estimates of $3.7 billion from Wall Street. The company reported a net loss of $41 million, but on an adjusted basis, earnings were $0.13 per share, which came in $0.02 ahead of estimates.

Yandex N.V. (NASDAQ: YNDX) – For an in-depth report on Yandex N.V. follow:

Shares of Yandex closed down about 10% this past Friday with nearly 28.2 million shares traded. The stock hit a new 52-week low of $21.70 during intra-day trading. Concerns rose that the company could face pressures from Internet control in Russia.

Vape Holdings, Inc. (OTC: VAPE) – For an in-depth report on Vape Holdings, Inc. follow:

VAPE shares closed down 17.37% with about 2.1 million shares traded. The stock was a big decliner in the OTC market despite any significant news. On April 24th, the company announced that it has over $100,000 in sales of its proprietary HIVE Ceramic line since it began processing orders in early April. The Company also has back orders for over $250,000 in future sales as they await arrival of the ceramics from the Company's manufacturing facility.

Cytokinetics, Incorporated (NASDAQ: CYTK) – For an in-depth report on Cytokinetics, Incorporated follow:

Shares of CYTK closed down nearly 65% on Friday with over 17.2 million shares traded. The stock was one of the biggest decliners on the NASDAQ and even hit a new 52-week low of $4.57 during intra-day trading. The company announced disappointing top-line results from its BENEFIT-ALS midstage study involving tirasemtiv. Tirasemtiv did not meet its primary efficacy endpoint of delivering a mean change from baseline in the ALS functional rating scale. 


Disclosure: is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.


Leave a comment...

Your Name